Reata Pharmaceuticals, Inc. (RETA)
| Market Cap | 3.30B |
| Revenue (ttm) | 2.22M |
| Net Income (ttm) | -311.90M |
| Shares Out | 36.73M |
| EPS (ttm) | -8.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 959,189 |
| Open | 89.96 |
| Previous Close | 89.38 |
| Day's Range | 88.29 - 90.61 |
| 52-Week Range | 18.47 - 95.00 |
| Beta | 1.27 |
| Analysts | Buy |
| Price Target | 112.91 (+25.82%) |
| Earnings Date | Mar 27, 2023 |
About RETA
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ... [Read more]
Financial Performance
In 2022, RETA's revenue was $2.22 million, a decrease of -80.71% compared to the previous year's $11.49 million. Losses were -$311.90 million, 4.88% more than in 2021.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for RETA stock is "Buy." The 12-month stock price forecast is $112.91, which is an increase of 25.82% from the latest price.
News
Reata (RETA) Stock Doubles This Year on Skyclarys FDA Nod
Reata Pharmaceuticals (RETA) stock more than doubles this year, owing to approval for its rare disease drug.
The Stock That Tripled in a Day
Texas-based biotechnology company Reata Pharmaceuticals, Inc. (NASDAQ:RETA) lulled shareholders to sleep in 2022. The news flow was light, the trading pattern sideways and volume virtually nonexistent...
Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical company focused on developing and commercializing novel th...
The quality of your clinical data drives everything, says Reata Pharma CEO Warren Huff
Warren Huff, CEO of Reata Pharmaceuticals, and CNBC's Meg Tirrell join 'Power Lunch' to discuss Reata's new drug for treating a rare neurological disorder receiving FDA approval.
Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug
Skyclarys is the first drug to be approved specifically for the treatment of Friedreich's ataxia and is also Reata Pharmaceuticals' (RETA) first commercial product
Cytokinetics will seek international approval for drug following FDA rejection, says CEO Robert Blum
Cytokinetics President and CEO Robert Blum joins 'Power Lunch' to discuss the FDA's rejection of the company's heart failure drug, how FDA approval increases shareholder value and future treatment pla...
Reata's stock jumps 175% in premarket trading after FDA approval
Shares of Reata Pharmaceuticals Inc. RETA soared about 175% in premarket trading on Wednesday, the day after the Food and Drug Administration approved Skyclarys, a treatment for Friedreich's ataxia, a...
Why Is Reata Pharmaceuticals (RETA) Stock Up 175% Today?
Reata Pharmaceuticals (NASDAQ: RETA) stock is rocketing higher on Wednesday following approval from the FDA for one of its drugs. The FDA approval covers the use of the company's SKYCLARYS as a treat...
Stocks in focus: Reata Pharmaceuticals stock soars after FDA-drug approval; Novavax falls after vaccine maker issues ‘substantial doubts' over future operations
Here are U.S. stocks in focus ahead of Wednesday's trading session:
Reata Soars on Approval for Rare Disorder Drug. Its Pipeline Impresses Analysts.
The FDA approves the pharmaceutical company's treatment for Friedreich's ataxia, which Citi analysts expect to generate peak U.S. revenue of around $1.2 billion.
FDA approves Reata's rare nervous-system drug amid questions about changing regulatory environment for neuroscience treatments
The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.'s treatment for Friedreich's ataxia, a rare inherited disease that causes damage to the nervous system.
Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich's Ataxia
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical company focused on developing and commercializing novel th...
Reata Pharmaceuticals, Inc. (RETA) Soars 6.3%: Is Further Upside Left in the Stock?
Reata Pharmaceuticals, Inc. (RETA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furthe...
Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will particip...
Reata (RETA) Q3 Earnings Beat, Stock Up on Pipeline Updates
Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.
Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Lags Revenue Estimates
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 8.09% and 62.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...
Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results ...
Reata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will repor...
Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting cli...
Reata (RETA) Up After FDA Scraps AdCom Meeting for NDA Filing
The FDA decides not to hold an advisory committee meeting for Reata Pharmaceuticals' (RETA) regulatory filing seeking approval for omaveloxolone in Friedreich's Ataxia.
Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 20.6%: Will It Continue to Soar?
Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further s...
Why Is Reata Pharmaceuticals (RETA) Stock Up 15% Today?
On a sharply down day at the tail end of the week, Reata Pharmaceuticals (NASDAQ: RETA) provided a dramatic counterpoint. While the benchmark S&P 500 index slipped near 2% down, RETA stock gained ove...
Reata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich's Ataxia
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, announced that the U.S. Food and D...
Reata Pharma (RETA) is Striving Hard Despite Pipeline Setbacks
Reata Pharmaceuticals (RETA) is yet to generate product revenues due to the lack of marketed drugs in its portfolio. However, two of its pipeline candidates are close to potential FDA approval.
Reata Pharmaceuticals, Inc. (RETA) Up 4.7% Since Last Earnings Report: Can It Continue?
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock?